Table 2 Pathologic findings.

From: Conjunctival ‘mucoepidermoid carcinoma’ revisited: a revision of terminology, based on morphologic, immunohistochemical and molecular findings of 14 cases, and the 2018 WHO Classification of Tumours of the Eye

Pt^a #^b	In-situ Unmod^c	In-situ Mod^d	Invasive Unmod^e	Invasive Mod^f	Stage, Grade (SCC)/ (ADC)^g	Group^h	PNIⁱ/LVI^j	Immunohistochemistry In situ component Invasive component					MAML2 FISH	HPV status
								CK7^k	CK17^k	BerEP4^k	p16^k	Ki67^l	Pos^m/Negⁿ	Pos/Neg (Assay)^o
1	In-situ MEC^p, in-situ SCC	CIN-Muc^q, in-situ SCC	No invasive	No invasive	Tis	NA^v	NA	2 + /2+ NA	2+/3 + NA	0 NA	1+ /1 + NA	30% NA	Neg	Neg (1)
2	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	No invasive	No invasive	Tis	NA	NA	3+ /2 +	3 + /3 +	NP^w	NP	NP	NP	NP
3	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	No invasive	No invasive	Tis	NA	NA	2+/1+	0	NP	NP	NP	Neg	NP
4	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	Basaloid SCC	Basaloid SCC	T2NxMx, G3/NAP	1	No/Yes	3+/4 + 3 + /4 +	3+/2 + 2 + /1 +	0 2 + /4+	3+/4 + 3 + 4 +	60% 60%	Neg	Neg (2)
5	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	MEC, aSCC^r	aSCC with muc dif^t	T4aNxMx, G2/G2	2	No/Yes	3 + /3 + 3 + /3 +	2+/2 + 2 + /2 +	0 1 + /1+	NP	NP	Neg	Neg (2)
6	In-situ SCC	In-situ SCC	MEC, aSCC	aSCC with muc dif	T4aN1M0, G2/NAP	2	No/Yes	2+/3 + 3 + /2 +	2+/3 + 3 + /2 +	0 0	3+/4 + 3 + /4 +	60% 45%	Neg	Pos (3) HPV16
7	In-situ SCC	In-situ SCC	MEC, aSCC	aSCC with muc dif	T4aNxMx, G3/NAP	2	No/No	0 2 + /3+	3+/3 + 1 + /3 +	0 0	3+/1 + 2 + /1 +	50% 45%	Neg	NP
8	in-situ MEC	CIN-Muc	Mi^s-MEC	Mi-SCC with muc diff	pT2NxMx, G2/NAP	2	No/No	3+/2 + 2 + /3 +	2+/2 + 2 + /2 +	0 0	3+/4 + 3 + /4 +	50% 50%	Neg	NP
9	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	MEC, SCC	aSCC with muc dif	T3N1Mx, G2/NAP	2	No/No	3+/2 + 4 + /4 +	3+/3 + 0	3 + /2 + 2 + /3 +	3 + /4 + 3 + /4 +	40% 40%	Neg	Pos (1) HPV18
10	No in-situ	No in-situ	MEC	aSCC with muc dif	T1NxMx, G2/NAP	2	Yes/No	NA 1 + /1 +	NA 1 + /1 +	NA 2 + /4 +	NA 0	NA 70%	Neg	Neg (1)
11	No in-situ	No in-situ	MEC	ASC^u	T2NxMx, G2/G2	3	No/No	NA 3 + /2 +	NA 3+/2+	NA 2+/2+	NA 2+/2+	NA 50%	Neg	Neg (1)
12	In-situ MEC, in-situ SCC	CIN-Muc, in-situ SCC	MEC, SCC	ASC	T4aNxMx, G2/G2	3	Yes/No	NP	NP	0 0	0 3+/1+	10% 20%	Neg	Neg (2)
13	In-situ MEC	CIN-Muc	MEC, SCC	ASC	T2NxMx, G3/G3	3	No/No	3+/4 + 3 + /4 +	2+/4 + 2 + /4 +	1+/4 + 1 + /4 +	3+/4 + 3 + /4 +	60% 60%	Neg	Neg (2,3)
14	No In-situ	No In-situ	MEC	ADC	T4aNxMx, NAP/G1	4	No/No	NA 3 + /4 +	NA 2 + /4+	NA 1+/1+	NA 3+/2+	NA 10%	Neg	Neg (2)

^aPT = patient, ^b# = number, ^cIn-situ component unmodified terminology, ^dIn situ component modified terminology, ^eInvasive component unmodified terminology, ^fInvasive component modified terminology
^gPathologic staging and grading in accordance with the AJCC guidelines for conjunctival carcinoma [6]; Grading is performed in the squamous cell carcinoma (SCC) and adenocarcinoma (ADC) components of the lesion, when both components are present
^hGrouping of invasive carcinoma in accordance with modified terminology
ⁱPNI = perineural invasion, ^jLVI = lymphovascular space invasion
^kCK7, CK17, BerEP4, and p16—staining expressed as intensity [0, 1+ (mild), 2+ moderate), 3+ (strong)] / percentage of positive cells[0, 1+ (1–25%), 2+ (26–50%), 3 + (51–75%), 4 + (76–100%)]
^lKi67—staining recorded as absolute percentage of cells in the tumour
^mPos = pospositive, ⁿNeg = negnegative
^oAssay – 1 = PCR, 2 = CRRNAScope, 3 = 3HPVish
^pMEC= mucoepidermoid carcinoma, ^qCIN-Muc = conjunctival intraepithelial neoplasia with mucinous differentiation, ^raSCC = acantholytic squamous cell carcinoma, ^sMi = microinvasive, ^tmuc dif = mucinous differentiation, ^uASC = adenosquamous carcinoma
^vNA = not applicable, ^wNP test not performed

Back to article page

Table 2 Pathologic findings.

Search

Quick links